Monika Szarszewska1, Anna Markowska2, Robert Jach3, Andrzej Marszałek4, Violetta Filas4, Wiesława Bednarek5, Anita Olejek6, Piotr Tomczak7, Stefan Sajdak8, Ewa Nowak-Markwitz9, Karolina Jaszczyńska-Nowinka10, Joanna Stanisławiak-Rudowicz10, Anna Gryboś11, Anita Chudecka-Głaz12, Marian Gryboś11, Krystyna Adamska13, Rodryg Ramlau7, Janina Markowska10, Paweł Knapp14. 1. Department of Gynecological Oncology, Poznan University of Medical Sciences, Poznan, Poland. Electronic address: monika.szarszewska@skpp.edu.pl. 2. Department of Perinatology and Gynecology, Poznan University of Medical Sciences, Poznan, Poland. 3. Gynecology and Obstetrics Department, Jagiellonian University Medical College, Krakow, Poland. 4. Department of Tumor Pathology and Prophylaxis, Poznan University of Medical Sciences, Greater Poland Cancer Centre, Poznan, Poland. 5. Chair and Clinic of Gynecological Oncology, University of Medical Sciences, Lublin, Poland. 6. Department of Gynecology Obstetrics and Gynecology Oncology, Medical University of Silesia, Bytom, Poland. 7. Chemiotherapy Department, Poznan University of Medical Sciences, Poznan, Poland. 8. Division of Gynecological Surgery, Poznan University of Medical Sciences, Poznan, Poland. 9. Department of Gynecology and Gynecologic Oncology, Poznan University of Medical Sciences, Poznan, Poland. 10. Department of Gynecological Oncology, Poznan University of Medical Sciences, Poznan, Poland. 11. Department of Gynecology and Obstetrics, Faculty of Health Science, Wroclaw Medical University, Wroclaw, Poland. 12. Chair and Department of Gynecological Surgery and Gynecological Oncology, Pomeranian Medical University, Szczecin, Poland. 13. Radiotherapy Department, Poznan University of Medical Sciences, Greater Poland Cancer Centre, Poznan, Poland. 14. Department of Gynecology and Gynecologic Oncology, Medical University of Bialystok, Bialystok, Poland.
Abstract
PURPOSE: Cerebral metastases develop in 10-30% of patients with breast cancer (BC) and in around 3.3 to 4% of patients with ovarian cancer (OC). The aim of the multicenter study is to investigate the correlation between the expression of estrogen alpha receptors (ERα), progesterone receptors (PR), human epidermal growth factor receptor 2 (HER2), stromal cell-derived factor 1 (SDF1) and its receptor C-X-C chemokine receptor type 4 (CXCR4), breast cancer metastasis suppressor 1 (BRMS1), astrocyte elevated gene 1 (AEG1), depending on the status of BRCA1 protein, in patients suffering from OC and BC with brain metastases. PATIENTS AND METHODS: The analysis included 51 patients: 29 with BC and 22 with OC, in whom brain metastases were disclosed. RESULTS: In most patients (65.5% of BC patients and 68.2% of patients with OC tumors) BRCA1 protein loss was found. No correlation was disclosed between the levels of ERα, PR receptors, HER2, SDF1, CXCR4, AEG1, BRMS1 and BRCA1 status, patient age, stage of disease advancement, grade of histological maturity of the cells, presence of metastases to lymph nodes. A statistically significant correlation was disclosed between the negative expression of PR receptors and a high expression of CXCR4 in patients with BC. High values of the AEG1 protein (linked to metastases) were detected alongside a high expression of BRMS1 (a suppressor of metastases). CONCLUSIONS: Patients with BC and OC and brain metastases have a frequent loss of BRCA1 expression. The role of ERα, PR, HER2, SDF1, CXCR4, AEG1, BRMS1 in metastatic process needs further studies.
PURPOSE: Cerebral metastases develop in 10-30% of patients with breast cancer (BC) and in around 3.3 to 4% of patients with ovarian cancer (OC). The aim of the multicenter study is to investigate the correlation between the expression of estrogen alpha receptors (ERα), progesterone receptors (PR), human epidermal growth factor receptor 2 (HER2), stromal cell-derived factor 1 (SDF1) and its receptor C-X-C chemokine receptor type 4 (CXCR4), breast cancer metastasis suppressor 1 (BRMS1), astrocyte elevated gene 1 (AEG1), depending on the status of BRCA1 protein, in patients suffering from OC and BC with brain metastases. PATIENTS AND METHODS: The analysis included 51 patients: 29 with BC and 22 with OC, in whom brain metastases were disclosed. RESULTS: In most patients (65.5% of BC patients and 68.2% of patients with OC tumors) BRCA1 protein loss was found. No correlation was disclosed between the levels of ERα, PR receptors, HER2, SDF1, CXCR4, AEG1, BRMS1 and BRCA1 status, patient age, stage of disease advancement, grade of histological maturity of the cells, presence of metastases to lymph nodes. A statistically significant correlation was disclosed between the negative expression of PR receptors and a high expression of CXCR4 in patients with BC. High values of the AEG1 protein (linked to metastases) were detected alongside a high expression of BRMS1 (a suppressor of metastases). CONCLUSIONS:Patients with BC and OC and brain metastases have a frequent loss of BRCA1 expression. The role of ERα, PR, HER2, SDF1, CXCR4, AEG1, BRMS1 in metastatic process needs further studies.